The clinical importance of conventional and quantitative liver function tests in liver transplantation

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 6, 2000, Pages 411-419

  Tanaka, Einosuke ^a   Inomata, S ^a   Yasuhara, H ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chlorzoxazone; Cytochrome P450; Drug metabolizing enzyme; Galactose; Human; Indocyanine green; Lidocaine; Liver function; Liver transplantation; Midazolam; Monoethylglycinexylidide

Indexed keywords

DEETHYLLIDOCAINE; LIDOCAINE;

DIAGNOSTIC VALUE; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; QUANTITATIVE DIAGNOSIS; REVIEW; RISK ASSESSMENT;

CHLORZOXAZONE; HUMANS; LIDOCAINE; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MIDAZOLAM;

EID: 0034534501     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00308.x     Document Type: Review

References (94)

1. Chronic parenchymal liver disease
2. Clinical chemistry and post-liver-transplant monitoring
3. Assessment of liver function: The current situation
4. Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation
5. The use of lidocaine as a test of liver function in liver transplantation
6. Assessment of liver function: Pre- and peritransplant evaluation
7. Importance of determination of monoethylglycinexylidide (MEGX) as a liver function test in hepatology and liver transplantation
8. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease
9. Evaluation of quantitative liver function tests in liver donors
10. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients
11. Donor rating in human liver transplantation: Correlation of oxygen consumption after revascularization with MEGX formation in donors
12. Lignocaine metabolite formation as a measure of pre-transplant liver function
13. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis
14. Assessment of liver function in the early postoperative period after liver transplantation with ICG, MEGX, and GAL tests
15. Selection criteria for liver transplant donors
16. Predictors of one-year pretransplant survival in patients with cirrhosis
17. Selection criteria for liver transplant donors
18. Assessment of pretransplant prognosis in patients with cirrhosis
19. Functional state of the donor liver and early outcome of transplantation
20. Reliability of the MEGX test in the selection of liver grafts
21. Lignocaine metabolism and MEGX production in the liver transplant donor
22. MEGX: From bench to bedside
23. MEGX as a test of donor liver function
24. Pre and post-transplant assessment of liver function in paediatric liver transplantation
25. Pre and post-transplant assessment of liver function in paediatric liver transplantation
26. Lignocaine metabolism and liver function testing in primary graft failure following orthotopic liver transplantation
27. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score
28. Limits of the MEGX test in the selection of liver grafts for transplantation
29. Safe use of liver donors with MEGX values less than 90 ng/mL
30. Histological comparison of donor livers and lidocaine metabolism in the utilization of organs for liver transplantation
31. Increased plasma endothelin concentrations in patients after liver transplantation and in liver cirrhosis
32. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient
33. Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation
34. Lidocaine metabolite formation in the liver donor as a predictive test for the safe and efficient introduction of cyclosporine in the recipient
35. Donor hyaluronic acid and MEGX levels do not accurately predict post-transplant liver function
36. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient
37. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors
38. The value of the donor MEGX test in predicting liver allograft recipient outcome
39. The role of dynamic and morphological studies in the assessment of potential liver donors
40. Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period
41. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates
42. The use of the lidocaine monoethylglycinexylidide test in the liver transplant recipient
43. Prognostic value of the monoethylglycinexylidide liver function test in assessing donor liver suitability
44. The lidocaine monoethylglycinexylidide test of liver function
45. Conventional and quantitative liver function tests after hepatic transplantation: A prospective long-term follow-up
46. Donor MEGX test fails to predict graft function after orthotopic liver transplant
47. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors
48. Early assessment of transplanted liver function: Lignocaine clearance test (MEGX)
49. Value of the in vitro or in vivo monoethylglycinexylidide test for predicting liver graft function
50. Conventional and quantitative liver function tests after hepatic transplantation: A prospective long-term follow-up
51. Orthotopic liver transplantation with preservation of portocaval flow compared with venovenous bypass
52. Acute cyclosporine toxicity after liver transplantation is predicted by the lidocaine monoethylglycinexylidide test in the donor
53. Prospective multivariate analysis of donor monoethylglycine xylidide (MEGX) testing in liver transplantation
54. Lidocaine metabolism in human liver microsomes by cytochrome P450, A4
55. Monoethylglycinexylidide formation kinetics (a novel approach to assessment of liver function)
56. Lidocaine metabolite formation as a early post-transplant liver function
57. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis
58. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis
59. Evaluation of lidocaine metabolite (monoethylglycinexylidide) as a liver function test
60. The monoethylglycinexylidide test is more useful for evaluating liver function than indocyanine green test: Case of patients a patient with remarkable decreased indocyanine green half-life
61. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease
62. Pharmacokinetic drug data
63. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors
64. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests
65. Monoethylglicinexylidide test: A prognostic indicator of survival in cirrhosis
66. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation
67. Use of midazolam as a human cytochrome P450, 3A probe: I. In vitro-in vivo correlations in liver transplant patients
68. Use of midazolam as a human cytochrome P450, 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
69. Galactose elimination capacity as a prognostic indicator in patients with fulminant hepatic failure
70. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study
71. Indocyanine green clearance in acute rejection after liver transplantation
72. Indocyanine green clearance in the evaluation of donor livers
73. A pilot study of indocyanine green clearance as an early predictor of graft function
74. Indocyanine green elimination test in orthotopic liver recipients
75. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease
76. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients
77. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: A study of mutations CYP2D6*3 and CYP2D6*4
78. Transplant recipients as organ donors: The domino transplant
79. Reuse of a Japanese familial amyloidotic polyneuropathy patient's liver for a cancer patient: The domino liver transplantation procedure
80. 'Domino' liver transplantation combined with multivisceral transplantation
81. Liver transplantation for familial amyloid polyneuropathy
82. Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy
83. Domino liver transplantation for familial amyloid polyneuropathy
84. Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuropathy
85. Related articles Domino liver transplantation for familial amyloid polyneuropathy: Optimal use of a scarce resource
86. Familial amyloidotic polyneuropathy: Domino liver transplantation
87. Sequential (domino) transplantation of the liver in a transthyretin-50 familial amyloid polyneuropathy - Special reference to cardiological diagnosis and complications
88. Transplantation of three adult patients with one cadaveric graft: Wait or innovate
89. Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy
90. The metabolism and excretion of trimethadione in patients with percutaneous transhepatic biliary drainage and renal dysfunction
91. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites
92. Clinical significance of the trimethadione tolerance test in chronic hepatitis: A useful indicator of hepatic drug metabolizing capacity
93. Trimethadione metabolistm as a probe drug to estimate hepatic oxiding capacity in human